Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-World Setting

Dulaglutide (Trulicity) treatment of patients with type 2 diabetes (T2D) and moderate to severe chronic kidney disease was associated with lesser estimated glomerular filtration rate (eGFR) decline compared to insulin glargine (glargine) in a clinical trial. This study examined the relationship between dulaglutide or glargine use and eGFR for adults with T2D using real-world data from a U.S. electronic health records from 10/25/2013 to 6/18/2017. There were 13,869 glargine and 1,222 dulaglutide patients included in the descriptive analyses. Patients with initial eGFR < 60 or < 30 mL/min/1.73m2 were more likely to be treated with glargine than dulaglutide (31.3% v 17.1%, p